Utilizing real-world external controls for regulatory decision-making

A biotech company needed to contextualize its Phase 1b/2a trial for mNSCLC patients with a specific mutation. Learn how Tempus constructed a real-world external control arm to provide a benchmark for their regulatory submission.

Read more

Biomarker strategy for an inhibitor in bladder cancer

Discover how Tempus’ multimodal data analysis helped a biotech partner identify a key biomarker in bladder cancer. This data-driven strategy de-risked clinical development and supported a successful $100 million financing round.

Read more

Impact of M2-like macrophage infiltration on RCC immunotherapy outcomes

Tempus Lens analysis reveals how immune profiling enhances macrophage predictive value

Read more